0
0

Responsibility in Drug Advertising Act of 2020

2/8/2022, 11:15 PM

Congressional Summary of S 3180

Responsibility in Drug Advertising Act of 2020

This bill prohibits direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.

Current Status of Bill S 3180

Bill S 3180 is currently in the status of Bill Introduced since January 9, 2020. Bill S 3180 was introduced during Congress 116 and was introduced to the Senate on January 9, 2020.  Bill S 3180's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of January 9, 2020

Bipartisan Support of Bill S 3180

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
0
Unaffiliated Sponsors
1
Total Number of Cosponsors
0
Democrat Cosponsors
0
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 3180

Primary Policy Focus

Health

Potential Impact Areas

- Drug safety, medical device, and laboratory regulation
- Marketing and advertising
- Prescription drugs

Alternate Title(s) of Bill S 3180

Responsibility in Drug Advertising Act of 2020
Responsibility in Drug Advertising Act of 2020
A bill to amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.

Comments